JOURNAL ARTICLE

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations

M A Province, M P Goetz, H Brauch, D A Flockhart, J M Hebert, R Whaley, V J Suman, W Schroth, S Winter, H Zembutsu, T Mushiroda, W G Newman, M-T M Lee, C B Ambrosone, M W Beckmann, J-Y Choi, A-S Dieudonné, P A Fasching, R Ferraldeschi, L Gong, E Haschke-Becher, A Howell, L B Jordan, U Hamann, K Kiyotani, P Krippl, D Lambrechts, A Latif, U Langsenlehner, W Lorizio, P Neven, A T Nguyen, B-W Park, C A Purdie, P Quinlan, W Renner, M Schmidt, M Schwab, J-G Shin, J C Stingl, P Wegman, S Wingren, A H B Wu, E Ziv, G Zirpoli, A M Thompson, V C Jordan, Y Nakamura, R B Altman, M M Ames, R M Weinshilboum, M Eichelbaum, J N Ingle, T E Klein
Clinical Pharmacology and Therapeutics 2014, 95 (2): 216-27
24060820
The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy regarding cytochrome P450 2D6 (CYP2D6) status and clinical outcomes in tamoxifen therapy. We performed a meta-analysis on data from 4,973 tamoxifen-treated patients (12 globally distributed sites). Using strict eligibility requirements (postmenopausal women with estrogen receptor-positive breast cancer, receiving 20 mg/day tamoxifen for 5 years, criterion 1); CYP2D6 poor metabolizer status was associated with poorer invasive disease-free survival (IDFS: hazard ratio = 1.25; 95% confidence interval = 1.06, 1.47; P = 0.009). However, CYP2D6 status was not statistically significant when tamoxifen duration, menopausal status, and annual follow-up were not specified (criterion 2, n = 2,443; P = 0.25) or when no exclusions were applied (criterion 3, n = 4,935; P = 0.38). Although CYP2D6 is a strong predictor of IDFS using strict inclusion criteria, because the results are not robust to inclusion criteria (these were not defined a priori), prospective studies are necessary to fully establish the value of CYP2D6 genotyping in tamoxifen therapy.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read
24060820
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.